Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies

Targeting the interleukin-23/17 axis in axial spondyloarthritis

(2016) Ananta Paine et al.   CURRENT OPINION IN RHEUMATOLOGY

Secukinumab (AIN457) in the treatment of ankylosing spondylitis

(2016) Jürgen Braun et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

IL-17A blockade ameliorates ankylosing spondylitis

(2016) João H. Duarte   Nature Reviews Rheumatology

The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment

(2015) H. Jethwa et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Iain B McInnes et al.   LANCET

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

(2015) Michael M. Ward et al.   ARTHRITIS CARE & RESEARCH

Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs

(2015) Neil A. Accortt et al.   Arthritis & Rheumatology

Adverse effects of TNF inhibitors in SpA: Are they different from RA?

(2014) Percival D. Sampaio-Barros et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis

(2014) Seung Min Jung et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Spondyloarthritis in China

(2013) Ju Rong et al.   CURRENT OPINION IN RHEUMATOLOGY

Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia

(2013) Sandra V. Navarra et al.   International Journal of Rheumatic Diseases

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

(2013) Dominique Baeten et al.   LANCET

Global prevalence of ankylosing spondylitis

(2013) L. E. Dean et al.   RHEUMATOLOGY

Effect of IL-17A blockade with secukinumab in autoimmune diseases

(2012) Dhavalkumar D Patel et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

(2011) J. Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

Similarities and differences between spondyloarthritis in Asia and other parts of the world

(2011) Shengli Zhang et al.   CURRENT OPINION IN RHEUMATOLOGY

The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-  inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China

(2011) M. Xu et al.   RHEUMATOLOGY

Comparison of recommendations for the use of anti-tumour necrosis factor therapy in ankylosing spondylitis in 23 countries worldwide

(2011) Rosaline van den Berg et al.   RHEUMATOLOGY

Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient

(2010) Pilar Martinez Montiel et al.   LIVER INTERNATIONAL

Safety and Clinical Responses in Ankylosing Spondylitis after Three Months of Etanercept Therapy

(2008) Chan-Bum Choi et al.   JOURNAL OF KOREAN MEDICAL SCIENCE